Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
France
/
Pharmaceuticals & Biotech
Create a narrative
Virbac
ENXTPA:VIRP Community
1
Narratives
written by author
0
Comments
on narratives written by author
5
Fair Values set
on narratives written by author
Create a narrative
Virbac
Popular
Undervalued
Overvalued
Virbac
WA
Analyst Price Target
Consensus Narrative from 9 Analysts
Future R&D And Facility Expansion Will Introduce New Products In Pet Care And Pharmaceuticals
Key Takeaways Strategic R&D investments and facility expansions aim to drive innovation, operational efficiency, and future revenue growth, potentially enhancing profitability. Robust M&A strategy and focus on U.S. and China markets are expected to boost geographic expansion, market share, and revenue growth despite cost pressures.
View narrative
€391.61
FV
17.6% undervalued
intrinsic discount
6.19%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Your Valuation for
VIRP
Virbac
Your Fair Value
€
Current Price
€322.50
0.4% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-3m
2b
2015
2018
2021
2024
2025
2027
2030
Revenue €1.8b
Earnings €190.7m
Advanced
Set as Fair Value